Valuation: Verastem, Inc.

Market Cap 51Cr 44Cr 41Cr 38Cr 71Cr 4.89TCr 72Cr 488.8Cr 192.02Cr 2.39TCr 190.41Cr 186.23Cr 8.24TCr P/E 2026 *
-3.64x
P/E 2027 * -5.15x
Enterprise Value 34Cr 30Cr 28Cr 25Cr 48Cr 3.3TCr 49Cr 329.73Cr 129.53Cr 1.61TCr 128.45Cr 125.62Cr 5.56TCr EV / Sales 2026 *
3.36x
EV / Sales 2027 * 1.67x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+0.70%
1 week+6.85%
Current month+51.05%
1 month+43.89%
3 months-8.99%
6 months-13.62%
Current year-25.26%
1 week 5.1
Extreme 5.1
5.9
1 month 3.43
Extreme 3.43
5.9
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
44.98
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Director/Board Member 60 26/05/2026
Director/Board Member 69 03/05/2017
Chairman 68 15/12/2025
Date Insider Type Main position Quantity % Market Cap.
22/06/26 Sell

Chief Financial Officer

-4,089 0.0066%
22/06/26 Sell

Chief Executive Officer

-20,871 0.0339%
21/05/26 Free

Director

1,08,000 0.1229%
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%+6.85%+9.90%-36.45% 51Cr
-3.42%+4.90%+61.15%+87.70% 5.6TCr
-1.65%-3.40%+50.33%+68.60% 5.37TCr
-2.14%-9.13%+2.74%+421.65% 2.33TCr
-0.47%-1.53%-18.61%-15.41% 2.32TCr
-5.95%-2.58%+30.67%-9.47% 2.06TCr
-1.85%-0.70%+30.62%-30.92% 1.78TCr
-4.55%-1.95%+192.65%+349.58% 1.61TCr
-6.91%-5.83%+26.53%+644.30% 1.59TCr
+0.23%-2.49%+24.26%+187.16% 1.4TCr
Average -2.60%+0.29%+41.03%+166.67% 2.41TCr
Weighted average by Cap. -2.80%-0.87%+44.82%+148.57%

Financials

2026 *2027 *
Net sales 10Cr 8.9Cr 8.23Cr 7.56Cr 14Cr 981.63Cr 15Cr 98Cr 39Cr 479.36Cr 38Cr 37Cr 1.65TCr 18Cr 16Cr 14Cr 13Cr 25Cr 1.72TCr 25Cr 171.94Cr 68Cr 839.22Cr 67Cr 66Cr 2.9TCr
Net income -17Cr -14Cr -13Cr -12Cr -23Cr -1.59TCr -24Cr -159.57Cr -63Cr -778.88Cr -62Cr -61Cr -2.69TCr -14Cr -12Cr -11Cr -11Cr -20Cr -1.37TCr -20Cr -136.96Cr -54Cr -668.49Cr -53Cr -52Cr -2.31TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.59TCr -24Cr -159.07Cr -62Cr -776.41Cr -62Cr -61Cr -2.68TCr -21Cr -18Cr -17Cr -16Cr -29Cr -2.02TCr -30Cr -202.06Cr -79Cr -986.28Cr -79Cr -77Cr -3.41TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
16/26/16 $5.770 +0.70% 19,85,572
15/26/15 $5.730 +2.87% 20,83,595
14/26/14 $5.570 +3.72% 30,04,355
13/26/13 $5.370 -2.89% 24,17,232
10/26/10 $5.530 +2.41% 29,89,325
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.770USD
Average target price
15.00USD
Spread / Average Target
+159.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock